Qyuns Therapeutics-B (02509): Phase III clinical study results of otokibart (QX005N) for prurigo nodularis presented as a breakthrough research oral presentation at EADV 2026

Zhito Finance APP News, Qyuns Therapeutics-B (02509) announced that recently, the Phase III clinical research results in China of otokibart (QX005N) for the treatment of prurigo nodularis (PN) were successfully selected for the Late Breaking News (LBN) session of the 35th European Academy of Dermatology and Venereology Congress (EADV Congress 2026) held in Vienna, Austria, and were presented as an Oral presentation. The EADV Congress is the largest in Europe and one of the most influential international conferences in the field of dermatology and venereology.